Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
Express Scripts
Mallinckrodt
Harvard Business School
Moodys

Last Updated: December 3, 2022

CLINICAL TRIALS PROFILE FOR ACALABRUTINIB


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Acalabrutinib

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02029443 ↗ ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia Active, not recruiting Acerta Pharma BV Phase 1/Phase 2 2014-01-30 This study is evaluating the safety and efficacy of a new Bruton tyrosine kinase (Btk) inhibitor, acalabrutinib, for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
NCT02112526 ↗ Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma Active, not recruiting Acerta Pharma BV Phase 1 2014-08-07 To characterize the safety profile of acalabrutinib in subjects with relapsed or refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma (DLBCL).
NCT02157324 ↗ Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia Active, not recruiting Acerta Pharma BV Phase 1 2014-08-18 This study is evaluating the safety and efficacy of the combined use of acalabrutinib and ACP-319, for the treatment of chronic lymphocytic leukemia (CLL)
NCT02180711 ↗ Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma Recruiting Acerta Pharma, LLC Phase 1/Phase 2 2015-02-01 Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL. Part 2: To characterize the activity of acalabrutinib alone or in combination with rituximab in subjects with R/R MZL, as measured by ORR. Part 3: To characterize the safety of acalabrutinib in combination with rituximab and lenalidomide in subjects with R/R FL
NCT02180711 ↗ Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma Recruiting Acerta Pharma BV Phase 1/Phase 2 2015-02-01 Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL. Part 2: To characterize the activity of acalabrutinib alone or in combination with rituximab in subjects with R/R MZL, as measured by ORR. Part 3: To characterize the safety of acalabrutinib in combination with rituximab and lenalidomide in subjects with R/R FL
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Acalabrutinib

Condition Name

Condition Name for Acalabrutinib
Intervention Trials
Chronic Lymphocytic Leukemia 30
Mantle Cell Lymphoma 22
Small Lymphocytic Lymphoma 13
Diffuse Large B Cell Lymphoma 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Acalabrutinib
Intervention Trials
Lymphoma 59
Leukemia, Lymphocytic, Chronic, B-Cell 44
Leukemia, Lymphoid 42
Leukemia 37
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Acalabrutinib

Trials by Country

Trials by Country for Acalabrutinib
Location Trials
United States 463
Canada 41
United Kingdom 33
Poland 24
France 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Acalabrutinib
Location Trials
Texas 36
California 32
New York 30
Washington 24
Ohio 24
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Acalabrutinib

Clinical Trial Phase

Clinical Trial Phase for Acalabrutinib
Clinical Trial Phase Trials
Phase 4 1
Phase 3 15
Phase 2/Phase 3 1
[disabled in preview] 82
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Acalabrutinib
Clinical Trial Phase Trials
Recruiting 60
Active, not recruiting 22
Completed 22
[disabled in preview] 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Acalabrutinib

Sponsor Name

Sponsor Name for Acalabrutinib
Sponsor Trials
Acerta Pharma BV 44
AstraZeneca 44
National Cancer Institute (NCI) 17
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Acalabrutinib
Sponsor Trials
Industry 113
Other 91
NIH 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
Medtronic
Harvard Business School
Boehringer Ingelheim
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.